Paid Clinical Trials in Billings, MT
As of August 2026, 129 paid clinical trials are recruiting in Billings, Montana. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Billings offers studies at sites including Billings Clinic Cancer Center for conditions such as Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Anatomic Stage II Breast Cancer AJCC v8. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Billings
Trials by drug in Billings
Filter results
Newly added in Billings
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
129 clinical trials
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Top Research Study Locations in Billings
Researchers run research studies in Billings, MT at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Billings Clinic Cancer Center | Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 | 87 |
| Saint Vincent Frontier Cancer Center | Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | 15 |
| Intermountain Health West End Clinic | Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma | 9 |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana | Melanoma Stage IV, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma | 7 |
| Saint Vincent Healthcare | Ovarian Carcinoma, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | 5 |
| Billings Clinic | Cystic Fibrosis, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2 | 5 |
| St. Vincent Frontier Cancer Center-Research | Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer | 4 |
| St. Vincent Frontier Cancer Center | Chronic Lymphocytic Leukemia, Leukemia, B-cell, Leukemia, Lymphocytic | 3 |
| Intermountain Healthcare | Early Breast Cancer, Primary Evans Syndrome (ES), Primary Immune Thrombocytopenia (ITP) | 2 |
| Billings Clinic - Billings | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension | 1 |
| Billings Clinic | Hypothyroidism | 1 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| Decentralized / At-Home Participation (U.S.) | Healthy Adult Participants | 1 |
| GSK Investigational Site | Multiple Myeloma, Newly Diagnosed Multiple Myeloma | 1 |
| Intermountain Health - Intermountain Health West End Clinic | Ovarian Cancer | 1 |
| Intermountain Health - St. Vincent Frontier Cancer Center | KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| Intermountain Health Saint Vincent Regional Hospital | Cervical Cancer | 1 |
| Intermountain Health West End Clinic- Gynecologic Oncology | Cervical Cancer | 1 |
| Massive Bio SYNERGY-AI site | BRCA Gene Rearrangement, Bladder Cancer, Breast Cancer | 1 |
| Montana Cancer Consortium NCORP | Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma | 1 |
| SCL Health - Cancer Centers of Montana | Breast Cancer | 1 |
| Saint Joseph Hospital - Cancer Centers - St. Vincent Frontier Cancer Center | Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Pancreatic Cancer | 1 |
| Saint Vincent Regional Hospital- Cancer Centers of Montana | Cervical Cancer | 1 |
| St Vincent Frontier Cancer Center | CLL, Chronic Lymphocytic Leukemia | 1 |
| St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute) | Advanced Breast Cancer, Early Breast Cancer | 1 |
Active & Upcoming Studies in Billings (2026)
Recruiting trials in Billings grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (109 active studies)
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial · Phase 3 · National Cancer Institute (NCI)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) · Phase 2 · National Cancer Institute (NCI)
Vaccines (1 active study)
Mental health & behavior (1 active study)
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (1 active study)
Neurology & pain (1 active study)
Cardiovascular (1 active study)
Common conditions studied in Billings
- Stage IVB Prostate Cancer AJCC v8 (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
- Chronic Lymphocytic Leukemia (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Lung Non-Small Cell Carcinoma (5 active studies)
- Ovarian Cancer (5 active studies)
Leading research sponsors in Billings
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- Merck Sharp & Dohme LLC
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Billings?
There are approximately 129 recruiting clinical trials in Billings, Montana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Billings pay participants?
Most recruiting trials in Billings compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Billings?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Billings?
The most common conditions under active study in Billings include Stage IVB Prostate Cancer AJCC v8 (7), Acute Myeloid Leukemia (6), Chronic Lymphocytic Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Billings?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Billings on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Billings?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Billings?
Recruiting research sites in Billings include Billings Clinic Cancer Center, Saint Vincent Frontier Cancer Center, Intermountain Health West End Clinic, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Billings right now?
The largest active categories in Billings are Cancer & tumors (109), Vaccines (1), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.